Danapha Pharmaceutical JSC (HSTC:DAN) NonCurrent Deferred Liabilities: ₫0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
31 GF Score
Price ₫32,800.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC NonCurrent Deferred Liabilities?

Danapha Pharmaceutical JSC HSTC:DAN 31 NonCurrent Deferred Liabilities is ₫0.00 Mil as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Danapha Pharmaceutical JSC's non-current deferred liabilities for the quarter that ended in . 20 was ₫0.00 Mil.

Danapha Pharmaceutical JSC NonCurrent Deferred Liabilities Related Terms

Danapha Pharmaceutical JSC NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC NonCurrent Deferred Liabilities Chart

Danapha Pharmaceutical JSC Annual Data
Trend
NonCurrent Deferred Liabilities

Danapha Pharmaceutical JSC Semi-Annual Data
NonCurrent Deferred Liabilities
HSTC:DAN
31GF Score
Danapha Pharmaceutical JSC HSTC:DAN
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of ₫0.00 Mil mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a NonCurrent Deferred Liabilities of ₫0.00 Mil as of . 20. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Danapha Pharmaceutical JSC and its competitors.
Is Danapha Pharmaceutical JSC's NonCurrent Deferred Liabilities too high?
Danapha Pharmaceutical JSC's current NonCurrent Deferred Liabilities is ₫0.00 Mil. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's NonCurrent Deferred Liabilities compare to ZTS and UTHR?
Danapha Pharmaceutical JSC's NonCurrent Deferred Liabilities of ₫0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Danapha Pharmaceutical JSC and its competitors. Danapha Pharmaceutical JSC's current NonCurrent Deferred Liabilities is ₫0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current NonCurrent Deferred Liabilities of ₫0.00 Mil. The current NonCurrent Deferred Liabilities is ₫0.00 Mil. Danapha Pharmaceutical JSC's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current NonCurrent Deferred Liabilities is ₫0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
31GF Score

Get the complete analysis for HSTC:DAN

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫32,800.00
Price